Pete joined Biogen in 2012, and for 7 years he was a member of the Bioassay and Gene Therapy group within the Analytical Development department (PO&T). There he supported the characterization and development of clinical stage protein biologic and AAV vector‑based gene therapy programs.
As part of the gene therapy revolution at bluebird bio, Russell is blending his expertise in biochemistry and molecular virology with QC and drug development experience to recode the way we develop genetic medicine. At bluebird, he has supported efforts ranging from late-stage vector platform analytics to the development of novel assays for the next generation of CAR‑T therapies.
Alexander Dobrovic's laboratory is at the forefront of a translational research ‑ clinical implementation interface that translates laboratory research findings into affordable diagnostics to benefit the patient population. Prof. Dobrovic has made a particular contribution to innovative methodology in cancer molecular diagnostics
At Merck, Dr. Paweletz successfully built platforms to look at disease biomarkers in body fluids and oversaw research activities spanning the spectrum from early‑stage discovery to the clinic.
Keiko Shinjo, MD, PhD, Associate Professor, Division of Cancer Biology, Nagoya University Graduate School of Medicine, Japan
Keiko Shinjo's research has been focused on the dynamic regulation of gene expression by epigenetic mechanisms in human cancers. She applied ddPCR technique to detect aberrant DNA methylation in circulating free DNA for diagnose cancer.
From March 2020, Sandi Deans has been part of the UK national COVID‑9 response team and is Head of Laboratory Validation and Quality Assurance for SARS‑CoV‑2 testing for mass testing.
Over the past years, Dr Soverini has cultivated a growing interest in the application of novel technologies as diagnostic tools.
Fernando Bastida is leading SARS‑CoV‑2 research in collaboration with scientist groups in Mexico to get better understanding of the COVID‑19 infection in qPCR negative cases, anti‑drug activity of some compounds and multi‑infection cases.
The example from SARS‑CoV‑2
Dr. Qiu has been leading the development of a variety of molecular diagnostic standards, such as COVID‑19 RNA reference material, IHC quantitative control, HRD reference standards etc., all of which have been developed with the collaboration of world‑class IVD companies to provide better solutions for quality control in clinical laboratory.
In 2020, Dr. Driscoll's group began testing wastewater on campus for the presence of SARS‑CoV‑2 using Droplet Digital PCR, and are currently expanding their efforts state‑wide.